Hopital Ambroise Pare — Clinical Trial Site

65 Registered trials

22 Currently recruiting

Organisation

Hopital Ambroise Pare

Location

Boulogne Billancourt, France

Identifier

ORG-100028433

Address

9 Avenue Charles De Gaulle, 92100, France

Departments

#40018: Rhumatologie
#98325005:Dermatologie
2304: Dermatologie
75
93125005:Dermatologie générale et oncologie
Anesthésie-réanimation
Cardiology
Centre d'Evaluation et de Traitement de la Douleur (CETD)
chirurgie digestive
Chirurgie Générale Digestive et Ontologique
Département de dermatologie
Department of Respiratory Diseases and Thoracic-Oncology
Department of Respiratory Diseases and Thoracic Oncology
Dermatologie generale et Oncologie
Dermatology
Dermatology and Oncology
Head of the Pain Center
Infectious diseases
Maladies respiratoires et Oncologie thoracique
Médecine intensive - réanimation
Medical ICU
Medical Oncology
N/A
néphrologie
Neurochirurgie
Oncologie
oncology
Pain Assessment and Treatment Centre
Pneumologie
Pneumologie et Oncologie Thoracique
Pneumology
Pneumology & Thoracic Oncology
Respiratory diseases and thoraci oncology
Respiratory diseases and thoracic oncology
Rhumatologie
Service de Pneumologie et Oncologie Thoracique
Service de Dermatologie
Service de Dermatologie Générale et Oncologie
Service de Pneumologie
Service de Pneumologie et Oncologie Thoracique
Service Pneumologie et Oncologie Thoracique
Thoracic Oncology

Clinical trials at this site (65)

Search interface

Efficacy and tolerance of nicotinamide supplementation during acute kidney injury: a prospective randomized double-blind trial Pending

2023-508664-30-00 Acute kidney injury 5
BICCS - Beta-lactam Intermittent versus Continuous infusion and Combination antibiotic therapy in Sepsis Pending

2024-516849-39-01 antibiotic therapy in Sepsis 5
Comparison of Landiolol versus standard of care for prevention of mortality in patients hospitalized for a septic shock with hypercontractli… Pending

2024-518251-31-00 patients hospitalized for a septic shock with hypercont 5
METAREM / META-1 - METAREM :Immunotherapy Master Trial for Advanced Cancers / META-1: Immunotherapy without chemotherapy for advanced lung c… Pending

2025-522655-26-00 METAREM:Patients with advanced cancer, as defined as un 4
Trial assessing treatment in patients with advanced Lung Cancer and Interstitial Lung Disease Pending

2025-522790-10-00 Non Small Cell Lung Cancer 4
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or… Pending

2025-523461-17-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANC 5
A Study to Learn about the Study Medicine called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive Stage Sma… Pending

2025-523522-41-00 Extensive-Stage Small Cell Lung Cancer 10
Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia after Distal Revascularization: a randomized, double-blind trial Pending

2025-524297-42-00 CLTI defined as Rutherford category 4 or 5 5
Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting

2025-521775-31-00 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutatio 5 2025-11-12
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better than Anti-PD1 Alone in Adult Participants with Resectable Stage 3 or 4… Recruiting

2022-502825-17-00 Melanoma 4 2024-10-07
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N… Recruiting

2023-503920-14-00 Non-Small Cell Lung Cancer (NSCLC) 5 2024-01-02
Study assessing the efficacy of etoposide free chemotherapy plus durvalumab in first line extensive disease Small Cell Lung Cancer Recruiting

2023-504670-38-00 Extensive disease Small Cell Lung Cancer 4 2023-11-17
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (The… Recruiting

2022-500966-82-00 Resectable locally advanced squamous cell carcinoma (SC 5 2020-03-11
A clinical trial of MK-1084, pembrolizumab, and chemotherapy in people with nonsmall cell lung cancer (MK-1084-013) Recruiting

2024-517337-41-00 Completely resected Stage IIA-IIIB (N2) KRAS G12C mutat 5 2026-05-12
Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma Recruiting

2024-519208-29-00 Pleural mesothelioma 4 2026-04-02
A trial to learn how effective and safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults wit… Recruiting

2024-520101-39-00 TROP2 NMR-positive advanced or metastatic non-squamous 5 2026-04-01
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in… Recruiting

2025-521627-78-00 Neoplasms, Lung 5 2026-01-28
Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting

2024-515658-26-00 Unresectable or Metastatic HER2 overexpressing and PD-L 5 2026-01-21
Study of zoldonrasib with or without daraxonrasib and other anticancer drugs in patients with RAS G12D-mutant non-small cell lung cancer (NS… Recruiting

2025-521147-21-00 Lung Cancer 4 2025-10-08
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting

2024-517780-24-00 Lung Cancer 5 2025-09-18
Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting

2024-515698-85-00 Locally Advanced or Metastatic Non-small Cell Lung Canc 5 2025-06-12
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy Recruiting

2024-514689-38-01 Pain Associated With Diabetic Peripheral Neuropathy 4 2025-05-12
MODULO Recruiting

2024-515793-27-01 HIV 5 2025-04-30